Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03536637 · ClinicalTrials.gov registry record · Phase 2

DMT310-001 Topical in the Treatment of Acne Vulgaris

A Phase 2 study, sponsored by Dermata Therapeutics.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target

NCT03536637: Completed Phase 2 study, sponsored by Dermata Therapeutics.

NCT03536637 is a Phase 2 study that has completed, run by Dermata Therapeutics. The registered enrollment target is 121 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03536637, a Phase 2 study, has completed, sponsored by Dermata Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target

Study Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.

Primary Outcome

Inflammatory and Noninflammatory

Interventions

  • DRUG Placebo
  • DRUG Hydrogen Peroxide
  • DRUG DMT310

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2018-05-22
Est. Completion 2019-01-28
Phase Phase 2
Dermata Therapeutics

5 total trials

What the finished NCT03536637 record still lists

NCT03536637 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03536637 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03536637 about?

NCT03536637 is a clinical study titled "DMT310-001 Topical in the Treatment of Acne Vulgaris". The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.

What is the current status of trial NCT03536637?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2018-05-22. Estimated completion is 2019-01-28.

What interventions are being tested in trial NCT03536637?

The interventions under investigation include: Placebo (DRUG), Hydrogen Peroxide (DRUG), DMT310 (DRUG).

Who is sponsoring clinical trial NCT03536637?

This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03536637's enrollment target sits among peer trials

121 567th of 2000 higher than 1,432 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03476681 · 121 participants · Phase 1

    Study of NEO-201 in Solid Tumors Expansion Cohorts

  • NCT04655118 · 121 participants · Phase 2

    Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

  • NCT04676802 · 121 participants · Phase 2

    Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone

  • NCT05169515 · 121 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03536637, the US trial registry maintained by the National Library of Medicine. NCT03536637 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.